Akriti G Jain, MD, FACP
LightNews LightNews
banner
akritigjain.bsky.social
Akriti G Jain, MD, FACP
@akritigjain.bsky.social
19 followers 46 following 5 posts
Leukemia and Myeloid Disorders, Cleveland Clinic
Assistant Professor, Case Western Reserve University
Posts Replies Media Videos
Reposted by Akriti G Jain, MD, FACP
targetedonc.bsky.social
Akriti Jain, MD, discusses what she is most looking forward to seeing presented at the upcoming 2024 American Society of Hematology Annual Meeting and Exposition. #ASH24 #ASH2024 @clevelandclinic.bsky.social

www.targetedonc.com/view/excitin...
Exciting Advances in AML Treatment: Jain on Key Highlights for ASH 2024
Akriti Jain, MD, discusses what she is most looking forward to seeing presented at the upcoming 2024 American Society of Hematology Annual Meeting and Exposition.
www.targetedonc.com
December 7, 2024 at 7:46 PM
akritigjain.bsky.social
Who knew we would have 5 options for frontline CML management! Read our review to find out how to choose!
anand-88-patel.bsky.social Anand Patel @anand-88-patel.bsky.social · Dec 15
a very useful review by @akritigjain.bsky.social et al on frontline TKI approaches in CML!

haematologica.org/article/view...
December 19, 2025 at 2:47 AM
akritigjain.bsky.social
Amazing talk using analogies from football on Tackling Anemia in MF by @aarongerds.bsky.social

#mpncongress #mpnsm
November 7, 2025 at 4:18 PM
Reposted by Akriti G Jain, MD, FACP
onclive.bsky.social
JAK Inhibitor Selection and Sequencing Strategies Are Key in #Myelofibrosis Management @akritigjain.bsky.social #oncology

www.onclive.com/view/jak-inh...
JAK Inhibitor Selection and Sequencing Strategies Are Key in Myelofibrosis Management | OncLive
Akriti Jain, MD, discusses treatment selection and sequencing of JAK inhibitors in myelofibrosis, emerging CALR-targeted research, and defining disease modification.
www.onclive.com
November 5, 2025 at 8:15 PM
Reposted by Akriti G Jain, MD, FACP
onclive.bsky.social
It's time for the #FiveUnder5 🕓, your go-to roundup of the top 5 #oncology videos of the week. @washumedicine.bsky.social @akritigjain.bsky.social @clevelandclinic.bsky.social @cityofhope.bsky.social @harvardmed.bsky.social

Watch the clips: 📽️: www.onclive.com/view/five-un...

#bcsm #mmsm
October 13, 2025 at 12:57 AM
Reposted by Akriti G Jain, MD, FACP
ascocancer.bsky.social
THIRD! Dr. Andrew Kuykendall presents VERIFY: rusfertide vs placebo for polycythemia vera. During weeks 20-32, more patients who received rusfertide achieved a clinical response, 76.9 vs 32.9%, p<0.0001. Patients received fewer phlebotomies and had less fatigue. #ASCO25
June 1, 2025 at 7:20 PM
akritigjain.bsky.social
Listen to our Cancer Advances Podcast on personalizing treatment of myelofibrosis related anemia!

@clevelandclinic.bsky.social

my.clevelandclinic.org/podcasts/can...
Personalizing Treatment of Myelofibrosis-Associated Anemia
Listen as Dr. Jain provides insights into the evolving therapeutic landscape, explaining how the field has expanded beyond single-agent therapy.
my.clevelandclinic.org
July 10, 2025 at 1:53 AM
akritigjain.bsky.social
My first @bloodjournal.bsky.social article!
January 19, 2025 at 11:28 PM
akritigjain.bsky.social
Let’s Go Buffalo!
@buffalo-bills.bsky.social
January 19, 2025 at 11:20 PM